valu usd unless otherwis note
tender offer ep tailwind rais
view upsiz cash tender offer
may provid much annual benefit non-gaap
ep estim also adjust new euro debt
yesterday announc upsiz cash tender offer
offer structur two bucket first tender offer
note second tender offer
maximum tender offer prior tender offer
expir juli earli tender date juli separ
announc price public offer senior note
use purchas note cash tender offer transact
reduc interest expens manag
expect debt refinanc leverag neutral
feel comfort high end ep guid
estim annual ep benefit cash tender offer
off-set new euro debt could much given
transact expect complet late
expect materi impact howev estim total
annual interest expens save cash tender offer off-set
new euro debt would manag let interest
expens save fall bottom line total interest expens
decreas fce vs impli
interest expens guid
current debt restructur program latest lever manag
pull off-set tax headwind back march complet
debt restructur issu lower-interest debt reduc
higher-interest dollar-denomin debt princip valu
result annual interest expens save save
interest expens debt restructur program one step
manag undertaken toward lessen impact higher
tax rate guidanc possibl offset
acceler benefit on-going enterpris excel program
increas ep estim pt increas
ep guidanc vs fce
increas y/i also increas ep
fce increas y/i assum full
offer fulfil drop portion total interest expens
save bottom line final slightli increas pt
prior base price-to-earnings multipl updat
ep
price prior trade day market close estimate unless otherwis note
forecast least organ growth cvg
rtg mitg expect grow around
diabet group higher rate believ around
guidanc impli ww revenu close
requir addit year estim
therapi innov contribut approxim half
revenu growth balanc come global expans
especi emerg market value-bas health care
tavr micra reveal linq remain key growth
driver cvg five high-growth market within cvg
tavr diagnost mid-teen follow endoven
atrial fibril lvad high singl digit low doubl
digit plan introduc next gener tavr
pend regulatori approv eu low-
risk indic enhanc micra significantli
expand potenti market next-
gener icm reveal linq also schedul launch
double-digit growth emerg market continu
em revenu increas compris
ww revenu approxim em revenu
came greater china middl east africa
latin america switch indirect direct
distribut major impact em growth
margin also made infrastructur invest key
market enabl market access improv penetr
bp increas everi year exclud fx june
investor day compani met target bp
forecast bp ebit margin expans weight
toward enterpris excel program lie
heart achiev target combin target
cc revenu growth ebit margin along debt
reduct lead target compound-annual-growth-rate ep
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i key assumpt underli
ep estim mid-single-digit cc growth
basi point cc oper margin expans
fiscal year excess free cash flow dividend
 deploy primarili share buy-back target price-to-earnings
price-to-earnings ntm averag share
upsid scenario base price-to-earnings multipl
ep y/i key assumpt
underli ep estim mid/high-single-
digit revenu growth achiev
combin accret superior perform
neurosurgeri diabet surgic innov
basi point oper margin expans
downsid scenario base price-to-earnings multipl
ep y/i key assumpt underli
ep estim low-single-digit cc revenu growth
flat oper margin year-over-year
materi contribut share repurchas
price target base ep estim y/i target
price-to-earnings price-to-earnings ntm averag share key assumpt
underli ep estim mid-single-digit organ top-line growth
driven new launch continu strength core franchis basi point
oper margin expans compani realiz benefit
enterpris excel program place excess free cash flow
dividend deploy primarili share buy-back price target basi
risk rate price target
lacklust growth key franchis includ pace defibril system atrial
fibril tavr drug-elut stent surgic innov brain pain therapi spine
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur weak
util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
interest expens net
